These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26548547)

  • 21. In vitro and in silico studies of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitory activity of the cowpea Gln-Asp-Phe peptide.
    Silva MBCE; Souza CADC; Philadelpho BO; Cunha MMND; Batista FPR; Silva JRD; Druzian JI; Castilho MS; Cilli EM; Ferreira ES
    Food Chem; 2018 Sep; 259():270-277. PubMed ID: 29680054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Silico and In Vitro Analysis of Tacca Tubers (
    Rachmawati R; Idroes R; Suhartono E; Maulydia NB; Darusman D
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500698
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular protective properties of kiwifruit extracts in vitro.
    Jung KA; Song TC; Han D; Kim IH; Kim YE; Lee CH
    Biol Pharm Bull; 2005 Sep; 28(9):1782-5. PubMed ID: 16141561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro screening for β-hydroxy-β-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
    Iqbal D; Khan MS; Khan A; Khan MS; Ahmad S; Srivastava AK; Bagga P
    Biomed Res Int; 2014; 2014():762620. PubMed ID: 24883325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.
    Lin SH; Huang KJ; Weng CF; Shiuan D
    Drug Des Devel Ther; 2015; 9():3313-24. PubMed ID: 26170618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association with Monoclonal Antibody Promotes Intracellular Delivery of Lycopene.
    Petyaev IM; Zigangirova NA; Tsibezov VV; Morgunova EY; Bondareva NE; Kyle NH; Bashmakov YK
    Monoclon Antib Immunodiagn Immunother; 2018 Jun; 37(3):147-152. PubMed ID: 29901419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor from Pueraria thunbergiana.
    Kim HJ; Lee DH; Hwang YY; Lee KS; Lee JS
    J Agric Food Chem; 2005 Jul; 53(15):5882-8. PubMed ID: 16028969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
    Tachibana-Iimori R; Tabara Y; Kusuhara H; Kohara K; Kawamoto R; Nakura J; Tokunaga K; Kondo I; Sugiyama Y; Miki T
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):375-80. PubMed ID: 15548849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ameliorations in dyslipidemia and atherosclerotic plaque by the inhibition of HMG-CoA reductase and antioxidant potential of phytoconstituents of an aqueous seed extract of Acacia senegal (L.) Willd in rabbits.
    Charan J; Riyad P; Ram H; Purohit A; Ambwani S; Kashyap P; Singh G; Hashem A; Abd Allah EF; Gupta VK; Kumar A; Panwar A
    PLoS One; 2022; 17(3):e0264646. PubMed ID: 35239727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative tolerability of the HMG-CoA reductase inhibitors.
    Farmer JA; Torre-Amione G
    Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.
    Shahbazi S; Kaur J; Kuanar A; Kar D; Singh S; Sobti RC
    Assay Drug Dev Technol; 2017; 15(7):342-351. PubMed ID: 29077483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 150 kDa glycoprotein isolated from Solanum nigrum Linne enhances activities of detoxicant enzymes and lowers plasmic cholesterol in mouse.
    Lee SJ; Ko JH; Lim K; Lim KT
    Pharmacol Res; 2005 May; 51(5):399-408. PubMed ID: 15749454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
    Verhulst A; D'Haese PC; De Broe ME
    J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.